Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Official title

A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)

Overview

This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizumab combination treatment. This trial will start with part A, Phase 2. During part A, Phase 2, preliminary efficacy and safety will be assessed, and the recommended Phase 3 dose (RP3D) will be identified when the data allow sufficient assessment of activity, safety, and tolerability. The Phase 3 part will start contingent upon the assessment in the Phase 2 part, taking into consideration the totality of information.

Interventions

• Drug Dato-DXd
  Dato-DXd will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of 4 mg/kg or 6 mg/kg in Part A or RP3D in Part B
• Drug Carboplatin
  Carboplatin will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of AUC 4.5 or 5.0 mg•min/mL
• Drug Cisplatin
  Cisplatin will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of 70 mg/m2
• Drug Gemcitabine
  Gemcitabine will be administered as an IV infusion at a dose of 1000 mg/m2 on Day 1 and 8 of every 3 week cycle.

Primary outcome measures

• Overall Response Rate - Part A (Phase 2) [Time frame: From Phase 2 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 34 months]
• Progression Free Survival as Assessed by Blinded Independent Central Review (BICR) - Part B (Phase 3) [Time frame: From Phase 3 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 38 months]
• Overall Survival - Part B (Phase 3) [Time frame: From Phase 3 randomization to death due to any cause, up to approximately 38 months]

Secondary outcome measures (3)

• Duration of Response - Part A (Phase 2) [Time frame: From the date of first documentation of objective tumor response to the date of the first documented radiographic disease progression or death due to any cause, whichever occurs first in Phase 2, up to approximately 34 months]
• Progression Free Survival as Assessed by Investigator - Part B (Phase 3) [Time frame: From Phase 3 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 38 months]
• Overall Response Rate - Part B (Phase 3) [Time frame: From Phase 3 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 38 months]

Eligibility criteria

Inclusion criteria

• Adult ≥18 years at the time the ICF is signed (if the legal age of consent is > 18 years old, then follow the local regulatory requirements).
• Histologically or cytologically confirmed unresectable locally advanced (T4b, any N; or any T, N 2-3) or metastatic (any T, any N, M1) urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra.

Participants with urothelial carcinoma (transitional cell) with squamous differentiation or mixed cell types are eligible if the histology is predominantly urothelial.

> Note 1: Urachal, small cell, and adenocarcinoma histology is not permitted.

• Note 2: Participants with la/mUC and a history of nonclinically active prostate cancer are allowed into the trial if:

• Participant does not have radiological metastasis of a proven prostate cancer.
• Participant with nonmetastatic prostate cancer do not have rising PSA (as determined using local testing by a validated or approved test method) defined as follows:

• Increase in PSA within 2 consecutive measurements separated by at least 1 week (completed within 4 weeks prior to consent or within Screening) and neither of the measurements with an absolute value above 2 ng/mL.
• Participant does not currently receive androgen deprivation therapy for the treatment of prostate cancer.
• Note 3: Participant with MIBC (T2-T4aN0M0 or T1-T4aN1M0) who received EV (or other agents with a vedotin payload) plus pembrolizumab (or other PD-1/PD-L1 inhibitors) as neoadjuvant/adjuvant therapy and progressed during treatment or within 12 months of treatment completion may be considered for enrollment, with approval from the Sponsor's Medical Monitor or designee.

• Must provide tumor tissue sample from archival tissue or newly obtained pretreatment biopsy for exploratory biomarker testing. Tumor tissue sample should not be collected from a lesion that was irradiated unless documentation can be provided confirming that the tumor tissue was collected at least 3 months after radiation and the lesion increased/appeared since radiation occurred. Tumor tissue must be of sufficient quantity (as defined in the Laboratory Manual).

a. Archival tissue collected after the most recent anticancer treatment and within 12 months before the informed consent date is preferred.

• Must be considered eligible to receive cisplatin- or carboplatin-containing chemotherapy, in the investigator's judgment. Participants eligible for cisplatin will receive cisplatin. If a participant received gemcitabine, carboplatin, or cisplatin for early UC in the adjuvant/neoadjuvant setting, the decision to rechallenge the participant with platinum therapy will be at the discretion of the investigator. Participants only receive carboplatin if they are ineligible for cisplatin. Participants are cisplatin-ineligible if they meet any of the following criteria:

• GFR <60 mL/min (GFR may be estimated by calculated CrCl using the Cockcroft-Gault formula, Modification of Diet in Renal Disease, or 24-hour urine)

For Phase 2 part:

• Participants with a GFR <60 mL/min but ≥50 mL/min but have no other cisplatin ineligibility criteria (items b, c, and d) may be considered cisplatin-eligible based on the investigator's clinical judgment.

For Phase 3 Part:

• Participants with borderline renal function CrCl ≥40 mL/min to <60 mL/min who have no other cisplatin ineligibility criteria (items b, c, and d) may receive cisplatin using a split-dose regimen, administered as cisplatin 35 mg/m2 on Days 1 and 8 of each 21-day cycle, for a maximum of 4 to 6 cycles.
• In participants with CrCl ≥50 mL/min to <60 mL/min, full-dose cisplatin may also be administered at the investigator's discretion, based on the overall clinical assessment.

The dosing schedule and dose level for Dato-DXd or gemcitabine are not altered when combined with either split-dose or full-dose cisplatin.

For both Phase 2 and Phase 3:

b. NCI-CTCAE Grade ≥2 audiometric hearing loss c. NCI-CTCAE Grade ≥2 peripheral neuropathy d. NYHA Class III heart failure

• Must have experienced radiographic progression or relapse during or after 1L of EV (or other agents with a vedotin payload) and pembrolizumab (or other PD-1/PD-L1 inhibitors).

Participants who discontinued EV (or other agents with a vedotin payload) and pembrolizumab (or other PD-1/PD-L1 inhibitors) in 1L due to toxicity are eligible if they have experienced disease progression following discontinuation. Participant who received EV (or other agents with a vedotin payload) plus pembrolizumab (or other PD-1/PD-L1) inhibitors in a neoadjuvant/adjuvant setting and progressed during treatment or within 12 months of treatment completion will also be considered for enrollment, after approval by the Sponsor's Medical Monitor or Sponsor's designee.

Exclusion criteria

• Has had prior systemic therapy other than the combination of EV and pembrolizumab for la/mUC. The following participants may be considered eligible after approval by the Sponsor's Medical Monitor or Sponsor's designee.

a. Participant who progressed during or after treatments with assets that include either anti-Nectin 4 or vedotin payload (MMAE or other microtubule inhibitors) combined with PD1/PD-L1 inhibitors in 1L la/mUC.

• Treatment with any of the following:

• History of an allogeneic bone marrow or solid organ transplant.
• Concomitant treatment with any prohibited medications in this protocol.
• Prior TROP2 directed ADC therapy.
• Uncontrolled or significant cardiovascular disease, including:

• QTcF interval >470 ms based on the average of triplicate 12-lead (ECG per local read) at screening.
• Myocardial infarction within 6 months prior to randomization.
• Uncontrolled angina pectoris within 6 months prior to randomization.
• NYHA Class 3 or 4 congestive heart failure at screening.
• Uncontrolled hypertension (resting systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg within 28 days before randomization that is not resolved despite maximal medical therapy).
• Has a history of non-infectious ILD/pneumonitis including radiation pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at Screening.
• Has clinically severe pulmonary compromise as judged by the investigator resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (eg, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc.) or any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement (eg, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.), or prior complete pneumonectomy.
• Toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet improved to NCI-CTCAE version 5.0 Grade ≤1 or baseline. Note: Participants may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to Grade >2 for at least 3 months prior to randomization and managed with standard of care treatment) which the investigator deems related to previous anticancer therapy, comprised of (including but not limited to):

• Anticancer therapy-induced neuropathy
• Residual toxicities from prior immunotherapy treatment: Grade 1 or Grade 2 endocrinopathies which may include:
• Hypothyroidism/ hyperthyroidism
• Type I diabetes
• Hyperglycemia
• Adrenal insufficiency
• Adrenalitis c. Skin hypopigmentation (vitiligo)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Sequential

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 38 centers

• Research Site — Fullerton
• Research Site — Glendale
• Research Site — La Jolla
• Research Site — Los Angeles
• Research Site — Orange
• Research Site — San Francisco
• Research Site — Aurora
• Research Site — Orange City
• … and 30 more centers

France · 27 centers

• Research Site — Angers
• Research Site — Bordeaux
• Research Site — Brest
• Research Site — Calais
• Research Site — Cedex 10
• Research Site — Créteil
• Research Site — Grenoble
• Research Site — La Chaussée-Saint-Victor
• … and 19 more centers

Japan · 20 centers

Center list to be confirmed — check the primary protocol.

Austria · 5 centers

• Research Site — Graz
• Research Site — Krems
• Research Site — Linz
• Research Site — Salzburg
• Research Site — Vienna

Germany · 4 centers

• Research Site — Eisleben Lutherstadt
• Research Site — Herne
• Research Site — Nürtingen
• Research Site — Stuttgart

China · 3 centers

• Research Site — Beijing
• Research Site — Chengdu
• Research Site — Guangzhou

Italy · 3 centers

• Research Site — Naples
• Research Site — Roma
• Research Site — Rozzano

Publications

• Galsky MD, Drakaki A, Basu A, McGregor B, Bedke J, Loriot Y, Kikuchi E, Guo J, Garmezy B, Sridhar SS, Singh P, Koshkin VS, Fleming M, Klauss G, Lin D, Liu C, Apolo AB, Powles T. TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma. Future Oncol. 2026 May;22(12):1387-1396. doi: 10.1080/14796694.2026.2663956. Epub 202 PMID 42142358

Identifiers

NCT: NCT07129993 · DS1062-328

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗